2-(2-Bromo-5-chlorophenyl)-2-methyl-1,3-dioxolane → 1-{2-[(7bR,11aS)1,2,7b,8,9,10,11,11a-octahydro-4H-pyrido[4,3-b][1,4]thiazepino[6,5,4-hi]indol-6-ylamino]-5-chlorophenyl}ethanone

HRID 23284

반응식

HRID 23284 반응식
Br[C:2]1[CH:7]=[CH:6][C:5]([Cl:8])=[CH:4][C:3]=1[C:9]1([CH3:14])[O:13]CCO1.[NH2:15][C:16]1[CH:17]=[C:18]2[C:22]3=[C:23]([CH2:25][S:26][CH2:27][CH2:28][N:21]3[C@H:20]3[CH2:29][CH2:30][N:31](C(OC(C)(C)C)=O)[CH2:32][C@@H:19]23)[CH:24]=1>>[CH2:28]1[N:21]2[C:22]3[C:18]([C@@H:19]4[CH2:32][NH:31][CH2:30][CH2:29][C@@H:20]42)=[CH:17][C:16]([NH:15][C:2]2[CH:7]=[CH:6][C:5]([Cl:8])=[CH:4][C:3]=2[C:9](=[O:13])[CH3:14])=[CH:24][C:23]=3[CH2:25][S:26][CH2:27]1

참가 물질

3

실험 절차

Using 2-(2-bromo-5-chlorophenyl)-2-methyl-1,3-dioxolane and following the procedures described in EXAMPLE 116, tert-butyl (7bR,11aS)-6-amino-1,2,7b,10,11,11a-hexahydro-4H-pyrido[4,3-b][1,4]thiazepino[6,5,4-hi]indole-9(8H)-carboxylate from EXAMPLE 33, Part B was converted into the title compound of EXAMPLE 150. 1H NMR (CDCl3) δ: 10.26 (s, 1H), 7.72 (d, 1H, J=2.2 Hz), 7.20 (dd, 1H, J=9.2, 2.6 Hz), 6.96 (d, 1H, J=9.2 Hz), 6.84 (d, 1H, J=1.8 Hz), 6.77 (d, 1H, J=1.9 Hz), 6.87 (s, 1H), 3.74 (ABq, 2H, JAB=15.6 Hz), 3.63-3.57 (m, 1H), 3.50-3.42 (m, 1H), 3.40-3.30 (m, 1H), 3.20-3.02 (m, 5H), 2.98-2.90 (m, 1H), 2.66-2.58 (m, 1H), 2.61 (s, 3H), 2.05-1.97 (m, 2H). LRMS (ES)+: 391.4 (M+H)+. LRMS (ES)+: 414.4 (M+H)+.

출처 및 근거

ORD 기록
ord-bc929c17e6c94b81937d281e7bb282cf
출처 데이터셋
uspto-grants-2005_02
특허 번호
US06849619B2

연결된 노트

불러오는 중…